Building a Portfolio of High Impact New Medicines
AMO Pharma is dedicated to making a positive difference for people affected by serious and debilitating diseases, particularly rare or orphan diseases. To do this, we first work to understand the areas of unmet need and the experience of living with any disease we are targeting. We then use our extensive experience in drug development to identify and advance therapies that can significantly improve clinical outcomes while offering the strongest opportunities for approval. With drugs designed to reduce disease burden, slow disease progression or reduce many or all symptoms of a disease, our goal is to give patients an opportunity for improved health and quality of life. Our passion for drug development is strengthened and inspired by many personal connections to the rare disease community held by members of our senior team.
The Expertise to Advance Promising Therapies for Novel Indications
In many cases, diseases and patients are underserved or neglected due to a lack of precedent in research and the inability to carefully assess results in pre-clinical and early stage clinical research. AMO Pharma applies a range of innovative clinical trial assessment tools and methodologies to unlock the full development potential of drugs that others might overlook.
The identification of therapies that have been previously studied in pre-clinical or clinical stage research presents opportunities to "jump start" development programs in new indications. We also apply a more modern approach to clinical research that invites key stakeholders (patients/researchers/physicians) to engage in an informed and collaborative process of drug development.
By understanding the mechanism of disease and disease pathways and then matching that understanding to therapies that have been widely studied and that offer proven safety and efficacy profiles, we can more clearly establish protocols and end points in clinical research to produce the targeted results needed for regulatory approval.
